Amendment No. 5 to Schedule 13D by Fresenius Medical Care AG

Fresenius Medical Care AG (FME AG) filed Amendment No. 5 to its Schedule 13D regarding its ownership of Humacyte, Inc. common stock. The amendment reflects a decrease in FME AG's beneficial ownership from 11.8% to 9.9%, solely due to an increase in the number of outstanding shares of Humacyte's common stock. FME AG did not acquire or dispose of any shares. The amendment also announces the appointment of Joseph E. Turk as a member of the Management Board, effective January 1, 2026. FME AG remains the indirect sole shareholder of Fresenius Medical Care Holdings, Inc., which owns 18,312,735 shares of Humacyte's common stock.